First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales

<br><strong>Background<br></strong> Several countries restricted the administration of ChAdOx1 to older age groups in 2021 over safety concerns following case reports and observed versus expected analyses suggesting a possible association with cerebral venous sinus thrombosis...

Full description

Bibliographic Details
Main Authors:	Kerr, S, Joy, M, Torabi, F, Bedston, S, Akbari, A, Agrawal, U, Beggs, J, Bradley, D, Chuter, A, Docherty, AB, Ford, D, Hobbs, R, Katikireddi, SV, Lowthian, E, de Lusignan, S, Lyons, R, Marple, J, McCowan, C, McGagh, D, McMenamin, J, Moore, E, Murray, J-LK, Owen, RK, Pan, J, Ritchie, L, Shah, SA, Shi, T, Stock, S, Tsang, RSM, Vasileiou, E, Woolhouse, M, Simpson, CR, Robertson, C, Sheikh, A
Format:	Journal article
Language:	English
Published:	Public Library of Science 2022

First dose ChAdOx1 and BNT162b2 COVID-19 vaccinations and cerebral venous sinus thrombosis: a pooled self-controlled case series study of 11.6 million individuals in England, Scotland, and Wales

Similar Items